All In Biotech

Investigational drug · Phase 3

Visugromab

Also called: CTL-002, Visugromab RDE, recommended expansion

Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

6

5 still active

All registered trials

6

Any phase or sponsor naming "Visugromab"

First trial start

2020

Dec 9, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Visugromab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Adult Solid Tumor
  • Metastatic Non-Squamous Non-Small Cell Lung Cancer
  • Unresectable or Metastatic Hepatocellular Carcinoma
  • Child-Pugh A Hepatocellular Carcinoma
  • Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
  • Cancer-associated Cachexia
  • Solid Tumor, Adult
  • Bladder Cancer

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Bladder and urothelial cancer · Liver cancer (hepatocellular carcinoma) · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Visugromab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 34 on PubMed

Also in development for Adult Solid Tumor

  • Carboplatin AUC-5Phase 22 trials

    Inhibrx Biosciences, Inc · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.